Affinity Asset Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Affinity Asset Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Sell	40,000 -15,000	-27%	-$7.68M	0.97%	32
2026 Q1	$28.8M	Buy	55,000 +23,869	+77%	+$11.4M	1.49%	22
2025 Q4	$18.1M	Sell	31,131 -83,869	-73%	-$42.8M	1.03%	33
2025 Q3	$52.7M	Buy	115,000 +35,000	+44%	+$13.1M	4.59%	5
2025 Q2	$24.2M	Hold	80,000	–	–	3.31%	10
2025 Q1	$26.5M	Sell	80,000 -2,500	-3%	-$821K	2.53%	10
2024 Q4	$25.5M	Sell	82,500 -17,500	-18%	-$4.92M	3.41%	8
2024 Q3	$21.2M	Sell	100,000 -10,000	-9%	-$2.56M	2.9%	8
2024 Q2	$30.8M	Sell	110,000 -5,000	-4%	-$1.19M	3.55%	4
2024 Q1	$30.7M	Buy	115,000 +15,000	+15%	+$3.53M	3.8%	5
2023 Q4	$23.1M	Buy	100,000 +15,000	+18%	+$2.62M	4.23%	4
2023 Q3	$12.4M	Sell	85,000 -7,500	-8%	-$1.41M	3.49%	8
2023 Q2	$21.4M	Sell	92,500 -500	-0.5%	-$135K	7.46%	1
2023 Q1	$22.5M	Buy	93,000 +23,000	+33%	+$6.27M	7.44%	2
2022 Q4	$20.3M	Sell	70,000 -30,000	-30%	-$2.93M	7.97%	2
2022 Q3	$6.5M	Hold	100,000	–	–	1.81%	15
2022 Q2	$7.16M	Buy	100,000 +25,000	+33%	+$1.84M	3.02%	11
2022 Q1	$7.36M	Buy	75,000 +10,000	+15%	+$843K	1.18%	14
2021 Q4	$5.51M	Buy	+65,000	New	+$5.34M	2%	21
2021 Q1	–	Sell	-5,000	Closed	-$556K	–	78
2020 Q4	$556K	Buy	+5,000	New	+$611K	0.29%	57

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Affinity Asset Advisors's MDGL Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Madrigal Pharmaceuticals (MDGL) stake by 27% in Q2 2026, selling an estimated $7.68M and leaving 40,000 shares worth $21.5M. The position accounts for 0.97% of the portfolio, ranked #32.

Affinity Asset Advisors first reported a position in MDGL in Q4 2020 and has held it in 20 quarters since. The position peaked at $52.7M in Q3 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Affinity Asset Advisors held 40,000 shares of Madrigal Pharmaceuticals worth $21.5M as of Q2 2026.
Affinity Asset Advisors sold 15,000 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.68M.
Madrigal Pharmaceuticals made up 0.97% of Affinity Asset Advisors's portfolio in Q2 2026, its #32 holding.
Affinity Asset Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
Affinity Asset Advisors's Madrigal Pharmaceuticals position peaked at $52.7M in Q3 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.